ATAI AtaiBeckley Inc.
Price Chart
Executive Summary
AtaiBeckley Inc. announced progress in advancing its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression (TRD), following a successful End-of-Phase 2 meeting with the FDA. The company highlighted Breakthrough Therapy Designation, positive Phase 2b results showing rapid and durable antidepressant effects, and a scalable commercial model aligned with existing interventional psychiatry workflows. Cash runway is reaffirmed through early 2029, with additional pipeline updates on EMP-01 and VLS-01.
Actionable Insight
Traders should monitor initiation of Phase 3 trials in Q2 2026 and subsequent enrollment progress as near-term catalysts. The scalable commercial model and FDA engagement reduce execution risk, supporting long-term upside. Consider positioning ahead of potential topline readouts in 2029.
Key Facts
- BPL-003 advanced to Phase 3 initiation in Q2 2026 following a successful FDA End-of-Phase 2 meeting.
- BPL-003 holds Breakthrough Therapy Designation and showed rapid antidepressant effects at Day 2 and durable improvements up to 8 weeks in Phase 2b.
- Two parallel Phase 3 pivotal trials (ReConnection-1 and ReConnection-2) to begin in Q2 2026, each with a 12-week double-blind phase and 52-week open-label extension.
- Cash runway extended into early 2029, covering key clinical milestones.
- Commercial model designed for integration into existing Spravato®-like workflows without requiring in-session psychotherapy.
- Positive Phase 2a results for EMP-01; VLS-01 Phase 2 topline data expected in H2 2026.
Financial Impact
No immediate financial impact, but de-risking of BPL-003 increases probability of future revenue. Cash runway supports value-inflection events through 2029.
Risk Factors
- Phase 3 trials may not replicate Phase 2b results.
- Regulatory delays or requirements beyond current expectations.
- Competition from other rapid-acting antidepressants like Spravato® or upcoming generics.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252558 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
11d ago
|
8-K
| $4.53 $4.50 | ▼ −0.66% | ▼ −1.06% | $3.92 (−13.47%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.15 $4.24 | ▲ +2.17% | ▲ +1.59% | $3.92 (−5.54%) |
|
Apr 27, 2026
7w ago
|
Press Release
| $4.34 $4.33 | ▼ −0.23% | ▲ +0.25% | $3.92 (−9.68%) |
|
Apr 20, 2026
7w ago
|
144
| $4.87 $4.71 | ▼ −3.29% | ▼ −4.30% | $3.92 (−19.51%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $3.76 $3.70 | ▼ −1.60% | ▼ −2.17% | $3.92 (+4.26%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $3.38 $3.54 | ▲ +4.73% | ▲ +4.17% | $3.92 (+15.98%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $3.65 $3.56 | ▼ −2.47% | ▼ −1.07% | $3.92 (+7.40%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.14 $4.06 | ▼ −1.93% | ▼ −1.83% | $3.92 (−5.31%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $3.39 $3.89 | ▲ +14.75% | ▲ +13.90% | $3.92 (+15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access